FY2027 Earnings Estimate for DTIL Issued By HC Wainwright

Precision BioSciences, Inc. (NASDAQ:DTIL) – Analysts at HC Wainwright upped their FY2027 earnings estimates for Precision BioSciences in a report issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.20 for the year, up from their prior estimate of $0.19. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2028 earnings at $0.40 EPS.

Precision BioSciences Trading Down 0.7 %

Precision BioSciences stock opened at $8.40 on Wednesday. The firm has a market capitalization of $60.77 million, a price-to-earnings ratio of 140.00 and a beta of 1.71. The firm has a 50 day simple moving average of $9.31 and a 200 day simple moving average of $10.05. Precision BioSciences has a 1-year low of $7.97 and a 1-year high of $19.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC purchased a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.